https://www.bicycletherapeutics.com/science-publications/preclinical-assessment-of-nuzefatide-pevedotin-nuzefa-formerly-bt5528-anti-tumor-activity-in-patient-derived-xenograft-models-of-pancreatic-ductal-adenocarcinoma/
Bicycle Therapeutics - Preclinical assessment of nuzefatide pevedotin (nuzefa; formerly BT5528)...
bicycle therapeuticspreclinicalassessmentformerly
https://www.stocktitan.net/news/BCYC/bicycle-therapeutics-announces-data-updates-across-zelenectide-p0y02ilts10o.html
Bicycle Therapeutics' Cancer Drug Shows Impressive 62.5% Response Rate in Breakthrough Clinical...
Dec 12, 2024 - Bicycle's zelenectide pevedotin demonstrates strong efficacy across multiple cancers, with remarkable response rates in breast cancer and urothelial cancer...
https://adisinsight.springer.com/drugs/800054776?error=cookies_not_supported&code=be098b2d-69a8-41f4-9c62-6de916b8d7eb
Research programme: dementia therapeutics - Bicycle Therapeutics - AdisInsight
Peptide therapeutics are being developed by Bicycle Therapeutics for neurodegenerative diseases including dementia. The company is utilising its proprietary
research programmedementiatherapeuticsbicycleadisinsight